Developer docs
API playgroundTry for free, no card

Search company profiles

Eriochem

Full company profile

uuid002gqjr

Namestring
Eriochem
Legal namestring
ERIOCHEM S.A.
Websiteurl
eriochem.com.ar
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Eriochem S.A. is an Argentine pharmaceutical laboratory founded in 2000 and headquartered in Colonia Avellaneda, Paraná, Entre Ríos, specializing in the development and manufacturing of generic and supergeneric oncology injectables in liquid and lyophilized forms. The company's commercial portfolio comprises ten branded products covering complex oncology molecules including decitabine, bortezomib, pemetrexed, vinorelbine, leuprolide acetate, oxaliplatin, zoledronic acid, bendamustine, melphalan, and gemcitabine. Its R&D infrastructure includes a dedicated Nanotechnology Research Department and three specialized development teams focused on programmed-release products, difficult-to-make generics, and supergenerics. The company holds 78 patents approved in major regulatory markets worldwide.

Eriochem operates a B2B technology-licensing go-to-market model rather than direct-to-pharmacy sales. Manufacturing is conducted at its Paraná facility under GMP compliance with both US Pharmacopeia (USP) and European Pharmacopeia (EP) standards, supported by a Quality Control function that employs 25% of company personnel and a separate Quality Assurance function that maintains regulatory compliance through internal and external audits. The company has secured Mercosur GMP certification, a positive Turkey Ministry of Health GMP inspection (2025), and markets its products through licensing partnerships with pharmaceutical companies across Latin America, Asia Pacific, Europe, and North America including the United States. Recent commercial engagement includes participation in CPHI Frankfurt (2025), DCAT New York City (March 2026), and FCE Pharma Brazil (June 2026).

The company's revenue model is built on licensing its proprietary generic and supergeneric formulations to international pharmaceutical partners, who then distribute the products under their own or co-branded labels. Pricing is not publicly disclosed. Eriochem is a privately held entity with no disclosed venture capital, private equity, or public shareholders; in July 2026 it announced changes to its shareholder structure, indicating an active ownership event. The company employs between 101 and 250 people and operates without disclosed subsidiaries, management team profiles, or acquisition activity.

Short descriptiontext

Eriochem S.A. is an Argentine pharmaceutical laboratory founded in 2000 that develops and manufactures generic and supergeneric oncology injectables, licensing its formulations to international pharmaceutical partners across Latin America, Asia Pacific, Europe, and North America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParana, Argentina
HQ citystring
Parana
HQ countrystring
Argentina
HQ regionstring
Latin America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic oncology injectables, supergeneric drug development, pharmaceutical technology licensing, lyophilized injectable manufacturing, nanotechnology pharmaceutical R&D
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Oncology Pharmaceuticals Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Generic Oncology Pharmaceuticals
TypeOne Time License
Description

Manufacturing and sale of generic oncology medications including branded generics (supergenerics). Revenue generated through product sales to international pharmaceutical partners and distributors.

eriochem.com.ar
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1Erioxel®
Description

Generic oncology product containing Decitabine for mantle cell lymphoma and multiple myeloma

eriochem.com.ar
+9 more records
Core offering1 text field

Eriochem is an Argentine pharmaceutical laboratory that develops and manufactures generic and supergeneric injectable oncology medications (liquid and lyophilized formulations). Its R&D division runs a Nanotechnology Research Department and three development teams focused on programmed-release products, difficult-to-make generics, and supergenerics. Products are commercialized internationally through technology licensing partnerships with pharmaceutical companies across Latin America, Asia Pacific, Europe, and North America.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Eriochem S.A. is an Argentine pharmaceutical laboratory specializing in generic oncological medications and super-generics with added-value technology. The company operates as a multi-Latin enterprise with vertical integration, developing and producing high-quality generic cancer medications. Its product portfolio consists of ten branded generic oncology products: Erioxel (Decitabine), Eugene (Bortezomib), Martxel (Pemetrexed), Vinorel (Vinorelbina), Lectrum (Leuprolide Acetate), Goxyral (Oxaliplatin), Eriophos (Zoledronic Acid), Eriotib (Bendamustina), Eriolan (Melphalan), and Eriogem (Gemcitabine). Eriochem's R&D division focuses on nanotechnology and three development teams: controlled-release product development, difficult-to-make generic development, and super-generic development. The company holds 78 patents approved in demanding markets worldwide.

Product and service1 record
1Erioxel®
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Eriochem has established multiple strategic alliances with pharmaceutical companies across Latin America, Asia Pacific, Europe, and North America. These partnerships involve the granting of technology licenses for proprietary generic oncology medications and registration patents. The company leverages its high quality standards, reliability, and project management efficiency to attract international partners seeking advanced generic pharmaceutical manufacturing capabilities.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian-headquartered global pharmaceutical company with oncology and complex generics portfolios. Directly comparable as a generic injectables manufacturer with emerging markets focus and global licensing/distribution model.

TypeDirect peer
Description

Indian generic pharmaceutical manufacturer with significant injectable generics and oncology portfolios. Comparable to Eriochem in generic injectable manufacturing focus and emerging markets presence through global licensing.

TypeDirect peer
Description

Indian-headquartered global pharmaceutical company with a strong specialty generics portfolio including oncology injectables. Directly comparable to Eriochem as a generic injectable manufacturer targeting global markets via licensing and direct sales.

4Eurofarma
TypeRegional player
Description

Brazilian-headquartered Latin American pharmaceutical company with oncology generics portfolio. Regional peer comparable to Eriochem in Latin American market presence and emerging market focus.

TypeRegional player
Description

South African-headquartered generic pharmaceutical manufacturer with global emerging markets presence. Comparable as a generic oncology manufacturer serving emerging markets through licensing partnerships.

TypeBroad incumbent
Description

Global leader in generic pharmaceuticals with extensive injectable and oncology portfolios. Broad incumbent comparable in generic injectables manufacturing but operating at vastly larger scale and direct distribution.

TypeDirect peer
Description

Major Indian generic pharmaceutical manufacturer with significant oncology injectable presence. Comparable to Eriochem in generic injectable oncology, though operating at substantially larger scale across more therapeutic areas.

8Sandoz (Novartis)
TypeBroad incumbent
Description

Global generic pharmaceuticals division with significant injectable and oncology presence. Broad incumbent comparable to Eriochem in generic injectables manufacturing, with substantially deeper resources and direct market access.

TypeBroad incumbent
Description

Global pharmaceutical company with extensive injectable generics portfolio including oncology. Broader incumbent with deeper resources and direct sales infrastructure compared to Eriochem's licensing model.

TypeDirect peer
Description

Jordanian-headquartered specialty generic injectable manufacturer with global reach. Comparable to Eriochem in injectable generics focus, GMP-certified manufacturing, and licensing-based international distribution.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eriochem

Generic Oncology Pharmaceuticals Manufacturingeriochem.com.ar

Eriochem S.A. is an Argentine pharmaceutical laboratory founded in 2000 that develops and manufactures generic and supergeneric oncology injectables, licensing its formulations to international pharmaceutical partners across Latin America, Asia Pacific, Europe, and North America.

What Eriochem does

Eriochem S.A. is an Argentine pharmaceutical laboratory founded in 2000 and headquartered in Colonia Avellaneda, Paraná, Entre Ríos, specializing in the development and manufacturing of generic and supergeneric oncology injectables in liquid and lyophilized forms. The company's commercial portfolio comprises ten branded products covering complex oncology molecules including decitabine, bortezomib, pemetrexed, vinorelbine, leuprolide acetate, oxaliplatin, zoledronic acid, bendamustine, melphalan, and gemcitabine. Its R&D infrastructure includes a dedicated Nanotechnology Research Department and three specialized development teams focused on programmed-release products, difficult-to-make generics, and supergenerics. The company holds 78 patents approved in major regulatory markets worldwide.

Eriochem operates a B2B technology-licensing go-to-market model rather than direct-to-pharmacy sales. Manufacturing is conducted at its Paraná facility under GMP compliance with both US Pharmacopeia (USP) and European Pharmacopeia (EP) standards, supported by a Quality Control function that employs 25% of company personnel and a separate Quality Assurance function that maintains regulatory compliance through internal and external audits. The company has secured Mercosur GMP certification, a positive Turkey Ministry of Health GMP inspection (2025), and markets its products through licensing partnerships with pharmaceutical companies across Latin America, Asia Pacific, Europe, and North America including the United States. Recent commercial engagement includes participation in CPHI Frankfurt (2025), DCAT New York City (March 2026), and FCE Pharma Brazil (June 2026).

The company's revenue model is built on licensing its proprietary generic and supergeneric formulations to international pharmaceutical partners, who then distribute the products under their own or co-branded labels. Pricing is not publicly disclosed. Eriochem is a privately held entity with no disclosed venture capital, private equity, or public shareholders; in July 2026 it announced changes to its shareholder structure, indicating an active ownership event. The company employs between 101 and 250 people and operates without disclosed subsidiaries, management team profiles, or acquisition activity.

Eriochem firmographics

Firmographics
Name
Eriochem
Legal name
ERIOCHEM S.A.
Website
https://eriochem.com.ar
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
101–250 employees
Short description
Eriochem S.A. is an Argentine pharmaceutical laboratory founded in 2000 that develops and manufactures generic and supergeneric oncology injectables, licensing its formulations to international pharmaceutical partners across Latin America, Asia Pacific, Europe, and North America.
Ownership category
akta.pro rank

Where Eriochem is headquartered

Location

Headquarters

HQ city
Parana
HQ country
Argentina
HQ region
Latin America

Offices1 record

Markets served

Eriochem business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. Generic Oncology Pharmaceuticals: Manufacturing and sale of generic oncology medications including branded generics (supergenerics). Revenue generated through product sales to international pharmaceutical partners and distributors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Eriochem product offering

Product offering

Core offering

Eriochem is an Argentine pharmaceutical laboratory that develops and manufactures generic and supergeneric injectable oncology medications (liquid and lyophilized formulations). Its R&D division runs a Nanotechnology Research Department and three development teams focused on programmed-release products, difficult-to-make generics, and supergenerics. Products are commercialized internationally through technology licensing partnerships with pharmaceutical companies across Latin America, Asia Pacific, Europe, and North America.

Product overview

Eriochem S.A. is an Argentine pharmaceutical laboratory specializing in generic oncological medications and super-generics with added-value technology. The company operates as a multi-Latin enterprise with vertical integration, developing and producing high-quality generic cancer medications. Its product portfolio consists of ten branded generic oncology products: Erioxel (Decitabine), Eugene (Bortezomib), Martxel (Pemetrexed), Vinorel (Vinorelbina), Lectrum (Leuprolide Acetate), Goxyral (Oxaliplatin), Eriophos (Zoledronic Acid), Eriotib (Bendamustina), Eriolan (Melphalan), and Eriogem (Gemcitabine). Eriochem's R&D division focuses on nanotechnology and three development teams: controlled-release product development, difficult-to-make generic development, and super-generic development. The company holds 78 patents approved in demanding markets worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • Erioxel®: Generic oncology product containing Decitabine for mantle cell lymphoma and multiple myeloma
  • Eugene®
  • Martxel®
  • Vinorel®
  • Lectrum®
  • Goxyral®
  • Eriophos®
  • Eriotib®
  • Eriolan®
  • Eriogem®

Products and services

  • Erioxel®

Companies that use Eriochem

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Eriochem technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Eriochem partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • International Pharmaceutical CompaniescoreStrategic or Co-development PartnerEriochem has established multiple strategic alliances with pharmaceutical companies across Latin America, Asia Pacific, Europe, and North America. These partnerships involve the granting of technology licenses for proprietary generic oncology medications and registration patents. The company leverages its high quality standards, reliability, and project management efficiency to attract international partners seeking advanced generic pharmaceutical manufacturing capabilities.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Eriochem competitors and assessment

Company assessment

Direct peers

  • Cipla: Indian-headquartered global pharmaceutical company with oncology and complex generics portfolios. Directly comparable as a generic injectables manufacturer with emerging markets focus and global licensing/distribution model.
  • Aurobindo Pharma: Indian generic pharmaceutical manufacturer with significant injectable generics and oncology portfolios. Comparable to Eriochem in generic injectable manufacturing focus and emerging markets presence through global licensing.
  • Intas Pharmaceuticals: Indian-headquartered global pharmaceutical company with a strong specialty generics portfolio including oncology injectables. Directly comparable to Eriochem as a generic injectable manufacturer targeting global markets via licensing and direct sales.
  • Dr. Reddy's Laboratories: Major Indian generic pharmaceutical manufacturer with significant oncology injectable presence. Comparable to Eriochem in generic injectable oncology, though operating at substantially larger scale across more therapeutic areas.
  • Hikma Pharmaceuticals: Jordanian-headquartered specialty generic injectable manufacturer with global reach. Comparable to Eriochem in injectable generics focus, GMP-certified manufacturing, and licensing-based international distribution.

Regional players

  • Eurofarma: Brazilian-headquartered Latin American pharmaceutical company with oncology generics portfolio. Regional peer comparable to Eriochem in Latin American market presence and emerging market focus.
  • Aspen Pharmacare: South African-headquartered generic pharmaceutical manufacturer with global emerging markets presence. Comparable as a generic oncology manufacturer serving emerging markets through licensing partnerships.

Broad incumbents

  • Teva Pharmaceutical Industries: Global leader in generic pharmaceuticals with extensive injectable and oncology portfolios. Broad incumbent comparable in generic injectables manufacturing but operating at vastly larger scale and direct distribution.
  • Sandoz (Novartis): Global generic pharmaceuticals division with significant injectable and oncology presence. Broad incumbent comparable to Eriochem in generic injectables manufacturing, with substantially deeper resources and direct market access.
  • Fresenius Kabi: Global pharmaceutical company with extensive injectable generics portfolio including oncology. Broader incumbent with deeper resources and direct sales infrastructure compared to Eriochem's licensing model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Eriochem social profiles

Digital presence

Eriochem compliance and trust

Trust signal

Compliance2 records

Eriochem financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eriochem leadership team

Management profile

Number of profiles

Eriochem funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eriochem M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eriochem

What does Eriochem do?

Eriochem is an Argentine pharmaceutical laboratory that develops and manufactures generic and supergeneric injectable oncology medications (liquid and lyophilized formulations). Its R&D division runs a Nanotechnology Research Department and three development teams focused on programmed-release products, difficult-to-make generics, and supergenerics. Products are commercialized internationally through technology licensing partnerships with pharmaceutical companies across Latin America, Asia Pacific, Europe, and North America.

Is Eriochem a public or private company?

Eriochem is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Eriochem founded?

Eriochem was founded in 2000. It employs 101 to 250 people.

Where is Eriochem based?

Eriochem is headquartered in Parana, Argentina, in the Latin America region.

How does Eriochem make money?

One revenue line is on record: generic Oncology Pharmaceuticals.

Who are Eriochem's main competitors?

Direct peers on record are Cipla, Aurobindo Pharma, Intas Pharmaceuticals, Dr. Reddy's Laboratories and Hikma Pharmaceuticals. Regional players are Eurofarma and Aspen Pharmacare. Broad incumbents are Teva Pharmaceutical Industries, Sandoz (Novartis) and Fresenius Kabi.

Does Eriochem have an API?

No public API is recorded for Eriochem.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales